{"id":45785,"date":"2026-01-15T17:29:14","date_gmt":"2026-01-15T20:29:14","guid":{"rendered":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/"},"modified":"2026-01-15T17:29:14","modified_gmt":"2026-01-15T20:29:14","slug":"a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan","status":"publish","type":"post","link":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/","title":{"rendered":"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan"},"content":{"rendered":"<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nA Samsung Epis Holdings (KRX: 0126Z0) apresentou hoje avan\u00e7os corporativos e atualiza\u00e7\u00f5es estrat\u00e9gicas durante a 44\u00aa edi\u00e7\u00e3o da J.P. Morgan Healthcare Conference.<\/p>\n<p id=\"news-body-cta\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">Este comunicado de imprensa inclui multim\u00e9dia. Veja o comunicado completo aqui: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\" alt=\"Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings\"><\/p>\n<p style=\"font-size:85%;\">Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings<\/p>\n<\/div>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n&#8220;2026 \u00e9 um ano monumental para n\u00f3s, pois entramos em um novo cap\u00edtulo para nossa empresa. Hoje, estamos anunciando seis novos candidatos em nosso pipeline de biossimilares, incluindo vedolizumabe e dupilumabe. Estamos fazendo grandes progressos para garantir 20 biossimilares em nosso portf\u00f3lio at\u00e9 2030&#8221;, disse Kyung-Ah Kim, presidente e diretora executiva (CEO) da Samsung Epis Holdings. &#8220;Tamb\u00e9m recebemos a aprova\u00e7\u00e3o para o pedido de novo medicamento experimental (IND) para o primeiro novo candidato terap\u00eautico desenvolvido pela Samsung Bioepis e planejamos avan\u00e7ar com nosso programa cl\u00ednico este ano. \u00c0 medida que ampliamos nosso portf\u00f3lio al\u00e9m dos biossimilares, continuaremos nossos esfor\u00e7os de desenvolvimento em conjugados anticorpo-f\u00e1rmaco (ADCs), aproveitando nossa plataforma inovadora de pesquisa e desenvolvimento para expandir as op\u00e7\u00f5es de tratamento vi\u00e1veis \u200b\u200bpara pacientes com necessidades n\u00e3o atendidas.&#8221;<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Atualiza\u00e7\u00f5es sobre Biossimilares da Samsung Bioepis<\/b><\/p>\n<ul class=\"bwlistdisc\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<li>\nAtualmente, a Samsung Bioepis conta com 11 biossimilares referentes a 10 mol\u00e9culas biol\u00f3gicas distintas, aprovados e lan\u00e7ados em mais de 40 pa\u00edses.<sup>1<\/sup> A empresa tem um biossimilar de pembrolizumabe em estudos cl\u00ednicos de Fase 1 e 3 e planeja assegurar um portf\u00f3lio de 20 biossimilares at\u00e9 2030.<\/p>\n<\/li>\n<li>\nO novo pipeline incluir\u00e1 dupilumabe, guselcumabe, ixequizumabe, fam-trastuzumabe deruxtecana-nxki, vedolizumabe e ocrelizumabe.<\/p>\n<\/li>\n<\/ul>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Atualiza\u00e7\u00f5es sobre Terapias Inovadoras<\/b><\/p>\n<ul class=\"bwlistdisc\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<li>\nEm dezembro de 2025, a FDA aprovou o pedido de IND para o SBE303. O SBE303 \u00e9 o primeiro ADC inovador da Samsung Bioepis, projetado para se ligar&agrave;Nectina-4, uma prote\u00edna de ades\u00e3o expressa especificamente em c\u00e9lulas tumorais, incluindo c\u00e2ncer urotelial, c\u00e2ncer de pulm\u00e3o e c\u00e2ncer de mama.<sup>2<\/sup> O estudo cl\u00ednico de Fase 1, primeiro em humanos, que tem como objetivo avaliar a seguran\u00e7a, tolerabilidade, efic\u00e1cia, farmacocin\u00e9tica e imunogenicidade do SBE303 em participantes com tumores s\u00f3lidos avan\u00e7ados e refrat\u00e1rios, est\u00e1 previsto para come\u00e7ar ainda este ano.<\/p>\n<\/li>\n<li>\nA Samsung Bioepis planeja ter um novo candidato terap\u00eautico inovador entrando em estudo cl\u00ednico a cada ano.<\/p>\n<\/li>\n<li>\nA Epis NexLab, nova subsidi\u00e1ria sob a Samsung Epis Holdings, lan\u00e7ou um projeto para desenvolver uma plataforma de entrega de f\u00e1rmacos baseada em pept\u00eddeos.<\/p>\n<\/li>\n<\/ul>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Portf\u00f3lio de Biossimilares da Samsung Bioepis<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>C\u00f3digo (Nome da Marca<sup>3<\/sup>)<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Nome N\u00e3o-Propriet\u00e1rio<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Produto de Refer\u00eancia<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Status<sup>4<\/sup><\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB5<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(IMRALDI\u2122, HADLIMA\u2122, ADALLOCE\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAdalimumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nHumira<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB4<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(BENEPALI\u2122, BRENZYS\u2122, ETOLOCE\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEtanercept<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEnbrel<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB2<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(FLIXABI\u2122, RENFLEXIS\u2122, REMALOCE\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nInfliximab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nRemicade<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB3<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(ONTRUZANT\u2122, SAMFENET\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nTrastuzumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nHerceptin<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB8<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(AYBINTIO\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nBevacizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAvastin<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB11<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(BYOOVIZ\u2122, AMELIVU\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nRanibizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLucentis<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB12<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(EPYSQLI\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEculizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSoliris<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB15<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(OPUVIZ\u2122, AFILIVU\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nAflibercept<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nEylea<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB16<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(OBODENCE\u2122, OSPOMYV\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nDenosumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nProlia<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB16<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(XBRYK\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nDenosumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nXgeva<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB17<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n(PYZCHIVA\u2122, EPYZTEK\u2122)<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nUstekinumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nStelara<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nLaunch<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nSB27<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nPembrolizumab<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nKeytruda<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nFase 1 e 3<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Candidatos a biossimilares da Samsung Bioepis em fase inicial de desenvolvimento<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\n<tr>\n<td class=\"bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>N\u00e3o-Propriet\u00e1rio Nome<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwrowaltcolor0 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\"><b>Produto de Refer\u00eancia<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDupilumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDupixent<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGuselkumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTremfya<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nIxekizumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTaltz<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nVedolizumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEntyvio<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOcrelizumab<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nOcrevus<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFam-trastuzumab deruxtecan-nxki<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nEnhertu<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Samsung Epis Holdings Co., Ltd.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nComo uma holding de investimentos dedicada aos setores biofarmac\u00eautico e de biotecnologia, a Samsung Epis Holdings tem como objetivo maximizar o valor corporativo e para os acionistas por meio de P&amp;D e investimentos proativos, al\u00e9m de otimizar as estrat\u00e9gias de neg\u00f3cios de suas subsidi\u00e1rias, Samsung Bioepis e Epis NexLab. A Samsung Epis Holdings continua a abra\u00e7ar desafios futuros e a impulsionar a inova\u00e7\u00e3o ao identificar novos vetores de crescimento e fortalecer plataformas globais de colabora\u00e7\u00e3o, estabelecendo assim uma base s\u00f3lida para o crescimento cont\u00ednuo de suas subsidi\u00e1rias. Para mais informa\u00e7\u00f5es, acesse:<a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungepisholdings.com&amp;esheet=54396262&amp;newsitemid=20260114101894&amp;lan=pt-BR&amp;anchor=www.samsungepisholdings.com&amp;index=1&amp;md5=4e0cd39ff36de40ba6c60bfcb03ecc5f\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungepisholdings.com<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Samsung Bioepis Co., Ltd.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nFundada em 2012, a Samsung Bioepis \u00e9 uma empresa biofarmac\u00eautica comprometida em tornar os cuidados de sa\u00fade acess\u00edveis a todos. Por meio de inova\u00e7\u00f5es no desenvolvimento de produtos e de um forte compromisso com a qualidade, a Samsung Bioepis busca se tornar a principal empresa biofarmac\u00eautica do mundo. A empresa continua a avan\u00e7ar um amplo pipeline de candidatos biol\u00f3gicos que abrangem diversas \u00e1reas terap\u00eauticas, incluindo imunologia, oncologia, oftalmologia, hematologia, nefrologia, neurologia e endocrinologia. Para mais informa\u00e7\u00f5es, acesse <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungbioepis.com&amp;esheet=54396262&amp;newsitemid=20260114101894&amp;lan=pt-BR&amp;anchor=www.samsungbioepis.com&amp;index=2&amp;md5=512ef0d41c25b11d240f923d355e3fd5\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungbioepis.com<\/a> e nos siga no <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis%2F&amp;esheet=54396262&amp;newsitemid=20260114101894&amp;lan=pt-BR&amp;anchor=LinkedIn&amp;index=3&amp;md5=23828a3973939a85de1efe0fd6bdacd8\" rel=\"follow\" shape=\"rect\" target=\"_blank\">LinkedIn<\/a> e <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSamsungBioepis&amp;esheet=54396262&amp;newsitemid=20260114101894&amp;lan=pt-BR&amp;anchor=X&amp;index=4&amp;md5=d798c1390eebd5b6cb8486352cc9f6d3\" rel=\"follow\" shape=\"rect\" target=\"_blank\">X<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><b>Sobre a Epis NexLab Co., Ltd.<\/b><\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nFundada em 2025 como subsidi\u00e1ria integral da Samsung Epis Holdings, a Epis NexLab dedica-se a impulsionar a inova\u00e7\u00e3o por meio do desenvolvimento de plataformas de biotecnologia de pr\u00f3xima gera\u00e7\u00e3o. Ao transformar tecnologias altamente escal\u00e1veis relacionadas a pept\u00eddeos em plataformas de desenvolvimento, a Epis NexLab est\u00e1 focada na descoberta de modalidades terap\u00eauticas inovadoras para o desenvolvimento de m\u00faltiplos candidatos terap\u00eauticos voltados a uma ampla gama de doen\u00e7as. Para mais informa\u00e7\u00f5es, acesse <a href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.samsungepisholdings.com&amp;esheet=54396262&amp;newsitemid=20260114101894&amp;lan=pt-BR&amp;anchor=www.samsungepisholdings.com&amp;index=5&amp;md5=3c1f4df46d9191e7d634653af4c17481\" rel=\"follow\" shape=\"rect\" target=\"_blank\">www.samsungepisholdings.com<\/a>.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><sup>1<\/sup> \u201cMais de 40 pa\u00edses\u201d refere-se a pa\u00edses nos quais a Samsung Bioepis possui presen\u00e7a comercial, com um ou mais produtos.<br \/>\n<br \/><sup>2<\/sup> Li K, Zhou Y, Zang M, Jin X, Li X. Therapeutic prospects of nectin-4 in cancer: applications and value. Front Oncol. 28 mar. 2024;14:1354543. doi: 10.3389\/fonc.2024.1354543. PMID: 38606099; PMCID: PMC11007101.<br \/>\n<br \/><sup>3<\/sup> Diferentes nomes de marca para diferentes regi\u00f5es e pa\u00edses.<br \/>\n<br \/><sup>4<\/sup> \u201cLaunch\u201d se refere ao lan\u00e7amento em um ou mais mercados e n\u00e3o necessariamente indica lan\u00e7amento em todos os mercados globais<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\">\nO texto no idioma original deste an\u00fancio \u00e9 a vers\u00e3o oficial autorizada. As tradu\u00e7\u00f5es s\u00e3o fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que \u00e9 a \u00fanica vers\u00e3o do texto que tem efeito legal.<\/p>\n<p xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260114101894r1&amp;sid=brdno&amp;distro=ftp\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\" xmlns=\"http:\/\/www.w3.org\/1999\/xhtml\"><span id=\"mmgallerylink-phrase\">Ver a vers\u00e3o original em businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/\" rel=\"follow\" target=\"_blank\">https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/<\/a><\/span><\/p>\n<p><b>Contato:<\/b><\/p>\n<p><b>Contato para a Imprensa<br \/>\n<\/b><\/p>\n<p>Anna Nayun Kim, <a href=\"mailto:nayun86.kim@samsung.com\" rel=\"follow\" shape=\"rect\">nayun86.kim@samsung.com<br \/>\n<\/a><\/p>\n<p>Yoon Kim, <a href=\"mailto:yoon1.kim@samsung.com\" rel=\"follow\" shape=\"rect\">yoon1.kim@samsung.com<\/a><\/p>\n<p><strong>Fonte: <\/strong><a href='http:\/\/www.businesswire.com\/portal\/site\/home\/' target='_blank'>BUSINESS WIRE<\/a><img src='https:\/\/api.dino.com.br\/v2\/news\/tr\/326105?partnerId=3197' alt=\"\" style=\"border:0px;width:1px;height:1px;\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Samsung Epis Holdings (KRX: 0126Z0) apresentou hoje avan\u00e7os corporativos e atualiza\u00e7\u00f5es estrat\u00e9gicas durante a 44\u00aa edi\u00e7\u00e3o da J.P. Morgan Healthcare Conference. Este comunicado de imprensa inclui multim\u00e9dia. Veja o comunicado completo aqui: https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings &#8220;2026 \u00e9 um ano monumental para n\u00f3s, pois entramos [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-45785","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"og:description\" content=\"A Samsung Epis Holdings (KRX: 0126Z0) apresentou hoje avan\u00e7os corporativos e atualiza\u00e7\u00f5es estrat\u00e9gicas durante a 44\u00aa edi\u00e7\u00e3o da J.P. Morgan Healthcare Conference. Este comunicado de imprensa inclui multim\u00e9dia. Veja o comunicado completo aqui: https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings &#8220;2026 \u00e9 um ano monumental para n\u00f3s, pois entramos [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/\" \/>\n<meta property=\"og:site_name\" content=\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T20:29:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\" \/>\n<meta name=\"author\" content=\"DINO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"DINO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/\"},\"author\":{\"name\":\"DINO\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"headline\":\"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan\",\"datePublished\":\"2026-01-15T20:29:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/\"},\"wordCount\":1019,\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114101894\\\/pt\\\/2691779\\\/4\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\",\"articleSection\":[\"Not\u00edcias Corporativas\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/\",\"name\":\"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114101894\\\/pt\\\/2691779\\\/4\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\",\"datePublished\":\"2026-01-15T20:29:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114101894\\\/pt\\\/2691779\\\/4\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260114101894\\\/pt\\\/2691779\\\/4\\\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#website\",\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/\",\"name\":\"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios\",\"description\":\"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/#\\\/schema\\\/person\\\/24f7b50e924d81f1023b69582993c0ff\",\"name\":\"DINO\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g\",\"caption\":\"DINO\"},\"url\":\"https:\\\/\\\/ocanal.com\\\/noticias\\\/corporativas\\\/author\\\/dino\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/","og_locale":"pt_BR","og_type":"article","og_title":"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","og_description":"A Samsung Epis Holdings (KRX: 0126Z0) apresentou hoje avan\u00e7os corporativos e atualiza\u00e7\u00f5es estrat\u00e9gicas durante a 44\u00aa edi\u00e7\u00e3o da J.P. Morgan Healthcare Conference. Este comunicado de imprensa inclui multim\u00e9dia. Veja o comunicado completo aqui: https:\/\/www.businesswire.com\/news\/home\/20260114101894\/pt\/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings &#8220;2026 \u00e9 um ano monumental para n\u00f3s, pois entramos [&hellip;]","og_url":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/","og_site_name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","article_published_time":"2026-01-15T20:29:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","type":"","width":"","height":""}],"author":"DINO","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"DINO","Est. tempo de leitura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#article","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/"},"author":{"name":"DINO","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"headline":"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan","datePublished":"2026-01-15T20:29:14+00:00","mainEntityOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/"},"wordCount":1019,"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","articleSection":["Not\u00edcias Corporativas"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/","url":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/","name":"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan - Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","isPartOf":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#primaryimage"},"image":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","datePublished":"2026-01-15T20:29:14+00:00","author":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff"},"breadcrumb":{"@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260114101894\/pt\/2691779\/4\/Kyung-Ah_Kim_President_and_CEO_of_Samsung_Epis_Holdings.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/a-samsung-epis-holdings-apresenta-atualizacoes-de-negocios-na-44a-conferencia-de-saude-do-j-p-morgan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/ocanal.com\/noticias\/corporativas\/"},{"@type":"ListItem","position":2,"name":"A Samsung Epis Holdings apresenta atualiza\u00e7\u00f5es de neg\u00f3cios na 44\u00aa Confer\u00eancia de Sa\u00fade do J.P. Morgan"}]},{"@type":"WebSite","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#website","url":"https:\/\/ocanal.com\/noticias\/corporativas\/","name":"Ocanal Not\u00edcias Corporativas - Empresariais, comunicados e neg\u00f3cios","description":"Tudo sobre o mercado empresarial, comunicados e neg\u00f3cios","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ocanal.com\/noticias\/corporativas\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/ocanal.com\/noticias\/corporativas\/#\/schema\/person\/24f7b50e924d81f1023b69582993c0ff","name":"DINO","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ca8348556b3dfd41c825da9ac5643583f369a1092022fb6057420d716f02be0c?s=96&d=mm&r=g","caption":"DINO"},"url":"https:\/\/ocanal.com\/noticias\/corporativas\/author\/dino\/"}]}},"_links":{"self":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/45785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/comments?post=45785"}],"version-history":[{"count":0,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/posts\/45785\/revisions"}],"wp:attachment":[{"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/media?parent=45785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/categories?post=45785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ocanal.com\/noticias\/corporativas\/wp-json\/wp\/v2\/tags?post=45785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}